2012年审评工作的主要亮点之一是欧洲药品管理局首次批准了一个基因治疗药物，即UniQure公司的阿利泼金(Glybera)，该药物用于严重或多重 胰腺炎发作患者的脂蛋白脂酶缺乏症治疗。
基于70个网页-相关网页
...格利贝拉(Glybera)是用于治疗脂蛋白脂肪酶缺乏症(LPLD)这种罕见的性遗传病，是第一个在西方国家获准上市的基因药物。
基于64个网页-相关网页
Two more attempts were made to get Glybera passed, both of which were rejected.
FORBES: Europe Takes The Lead Toward Approval Of First Gene Therapy Drug
But getting to this stage has been a challenging journey for Glybera as gene therapy has struggled to get traction among drug regulators.
Last month, the European Union approved Glybera for treatment of a rare genetic disease, making it the first gene-therapy medicine approved in the Western world.
WSJ: The Future of Medicine Is Now: Medical Innovations
应用推荐
模块上移
模块下移
不移动